Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment-Reference-Cited by-同舟云学术

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment

Published:2013-12-30 Issue:7 Volume:120 Page:968-975
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Badrising Sushil¹,van der Noort Vincent²,van Oort Inge M.³,van den Berg H. Pieter¹,Los Maartje⁴,Hamberg Paul⁵,Coenen Jules L.⁶,van den Eertwegh Alfons J. M.⁷,de Jong Igle J.⁸,Kerver Emile D.⁹,van Tinteren Harm²,Bergman Andries M.¹⁰

Affiliation:

1. Department of Oncology; Tergooi Hospital; Blaricum the Netherlands

2. Department of Biometrics; Netherlands Cancer Institute; Amsterdam the Netherlands

3. Department of Urology; Radboud University Nijmegen Medical Center; Nijmegen the Netherlands

4. Department of Oncology; St. Antonius Hospital, Nieuwegein; the Netherlands

5. Department of Oncology and Prostate Cancer Center; St. Franciscus Hospital; Rotterdam the Netherlands

6. Department of Oncology; Isala Clinic; Zwolle the Netherlands

7. Department of Oncology; VU University Medical Center; Amsterdam the Netherlands

8. Department of Urology; University Medical Center Groningen; Groningen the Netherlands

9. Department of Oncology; Onze Lieve Vrouwe Gasthuis (OLVG) Hospital; Amsterdam the Netherlands

10. Department of Medical Oncology; Netherlands Cancer Institute; Amsterdam the Netherlands.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.

1. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007

2. Cancer treatment and survivorship statistics, 2012;Siegel;CA Cancer J Clin,2012

3. The development of androgen-independent prostate cancer;Feldman;Nat Rev Cancer,2001

4. Androgen receptor signaling in androgen-refractory prostate cancer;Grossmann;J Natl Cancer Inst,2001

5. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance;Holzbeierlein;Am J Pathol,2004

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations;Expert Review of Clinical Pharmacology;2022-11-02

2. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective;BMC Health Services Research;2022-07-14

3. Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide;Frontiers in Pharmacology;2022-05-19

4. Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?;Frontiers in Pharmacology;2022-02-17

5. Rational Second-Generation Antiandrogen Use in Prostate Cancer;The Oncologist;2022-02-01